Walker R C
Division of Infectious Diseases and Internal Medicine, Mayo Clinic Rochester, Minnesota, USA.
Mayo Clin Proc. 1999 Oct;74(10):1030-7. doi: 10.4065/74.10.1030.
The quinolones are broad-spectrum antibacterial agents that have a novel mechanism of action. As synthetic compounds, these agents have been developed extensively to optimize antimicrobial activity, pharmacokinetic properties, and drug safety. Although earlier quinolones were effective only in the genitourinary and gastrointestinal tracts and only had activity against aerobic gram-negative bacteria, newer quinolones have wider potential applications and a broader spectrum of activity. Some of the newer quinolones will have a role in the treatment of community-acquired pneumonia and intra-abdominal infections. Ciprofloxacin remains the most potent quinolone against Pseudomonas aeruginosa. Among the quinolones, important differences exist in renal and hepatic elimination and dose-adjustment regimens. Although there are many Food and Drug Administration-approved indications for some of the newer quinolones, the quinolones are the drug of choice for only a few infections. Quinolone-resistant bacteria are being increasingly identified and emerge under selective pressure created by extensive use.
喹诺酮类是具有新型作用机制的广谱抗菌剂。作为合成化合物,这些药物已得到广泛研发,以优化抗菌活性、药代动力学特性和药物安全性。尽管早期喹诺酮类仅在泌尿生殖道和胃肠道有效,且仅对需氧革兰氏阴性菌有活性,但新型喹诺酮类有更广泛的潜在应用和更宽的活性谱。一些新型喹诺酮类将在社区获得性肺炎和腹腔内感染的治疗中发挥作用。环丙沙星仍然是对抗铜绿假单胞菌最有效的喹诺酮类药物。在喹诺酮类药物中,肾脏和肝脏消除以及剂量调整方案存在重要差异。尽管一些新型喹诺酮类有许多美国食品药品监督管理局批准的适应证,但喹诺酮类仅对少数感染是首选药物。喹诺酮类耐药菌越来越多地被发现,并且在广泛使用产生的选择压力下出现。